Hims & Hers Health, Inc.HIMS
NYSE • Healthcare
$24.20
P/E
44.45
PEG
—
FCF Yield
—
Rev Growth YoY
+3.8% YoY
Gross Margin
65.2%
Health Score
5/10
D/E Ratio
2.34
Confidence
LOW
Business Snapshot
Hims & Hers Health, Inc. operates a direct-to-consumer telehealth platform offering prescription and over-the-counter wellness products for conditions such as hair loss, sexual health, and dermatology. The company competes in the rapidly growing digital health market as a challenger to traditional healthcare providers and pharmacy chains, leveraging a personalised online consultation model. With trailing twelve-month revenue of $2.37 billion, the company has achieved meaningful scale but remains unprofitable on a GAAP basis. Its defining characteristic is a vertically integrated, brand‑aware DTC model that bypasses traditional insurance‑based reimbursement, giving it pricing flexibility and customer‑acquisition advantages.
Financial Health
Gross margin stands at 65.2%, down from 71.9% in the prior year, indicating margin compression. Net margin (TTM) is reported at 5.5%, though this figure appears in tension with the TTM net loss of -$13.23 million—a discrepancy that warrants caution...
Risk Assessment
- VALUATION — P/E of 44.45x is double the sector average of 22x, leaving little room for earnings disappointments.
- REVENUE DECELERATION — Revenue growth of 3.8% YoY masks a 1.6% sequential decline QoQ, signalling fading momentum.
- DEBT / LIQUIDITY — Debt-to-equity of 2.34x is elevated, requiring significant cash generation to service obligations.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- 52-WEEK POSITION — At $24.20, the stock trades 65.6% below its 52-week high of $70.43 and well below the midpoint of the annual range, reflecting persistent selling pressure....